More recently, integrative proteomic [10] and proteogenomic [12] characterization of LUAD and paired NAT, have revealed novel candidate metabolic pathways to support that cancer patient may benefit from therapies targeting the metabolic dependencies of their carcinomas, either as single therapeutic agents or in combination with other chemo- or immunotherapies [15–18]. This evidence concerns the gene BRD2 and carcinoma.